Novo Nordisk’s ongoing struggle with compounding pharmacies underscores a broader conflict in the pharmaceutical industry—balancing patent protection with access to essential medications. The company argues that the availability of compounded alternatives is cutting into the sales of Wegovy, its blockbuster obesity drug, and violating its intellectual property. While compounding pharmacies have long operated in a…

CoreWeave’s highly anticipated initial public offering (IPO) was expected to be a defining moment for the tech sector, particularly under the pro-business policies of Donald Trump’s second presidential term. Market optimism had been building around the prospect of reduced regulatory oversight and tax incentives, which many believed would create a favorable environment for high-growth technology…

In a bold declaration at its recent Annual General Meeting, Novo Nordisk’s CEO reaffirmed his confidence in the company’s next-generation obesity drug candidate, CagriSema. Despite trial results that fell short of the lofty expectations set by internal targets, leadership insists that the product will play an “important” role in the future of weight loss treatments.…

Dating apps, once solely focused on helping users find romantic partners through digital interactions, are now redefining their role in social networking. As engagement on these platforms declines, companies are pivoting toward facilitating real-world connections. This shift signals a growing recognition that digital interactions alone are not enough to foster meaningful relationships.  The expansion beyond…

Google Quantum AI’s director of hardware, Julian Kelly, has boldly stated that practical quantum computing applications are approximately five years away. This prediction carries significant weight in the tech community, suggesting that advanced simulations and complex problem-solving tasks—which are beyond the capabilities of today’s classical computers—could soon become a reality. The prospect of quantum computers…